stars 1 stars 2 stars 3

At Boston Interactome, we’re pioneering a breakthrough in biotechnology by precision mapping the human protein interactome to develop next-generation therapies. Our goal is to eliminate drug side effects entirely and usher in a new era of safer, more targeted treatments. We’re targeting CNS disorders, in particular cognitive decline and addiction. The unmet need is significant - millions of patients are suffering from these conditions but no therapeutic options exist that address the drivers of disease. We aim to change that. These disorders are characterized by aberrant PPIs in a class of multisubunit protein complexes known as epigenetic protein complexes. Their dysregulation leads to the long-term neuronal plasticity underpinning these disorders. Our platform lets us target this class of proteins for the first time. Previous efforts that targeted whole epigenetic proteins showed therapeutic efficacy - but unacceptable safety profiles. That is why we think we can win: these targets are only accessible to the PPI approach

Employees 4 (3 on RocketReach)
Founded 2024
Address 127 Western Ave, Boston, Massachusetts 02134, US
Industry Biotechnology Research

Boston Interactome Questions

Oliver Weisser is the Co-Founder and CEO of Boston Interactome.

3 people are employed at Boston Interactome.

Boston Interactome is based in Boston, Massachusetts.

Top Boston Interactome Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users